2 months Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,080.00 at Barclays MarketBeat
Barclays dropped their price target on Regeneron Pharmaceuticals from $1,220.00 to $1,080.00 and set an “overweight” rating on the stock in a research note on Wednesday.
Nasdaq 100 · Pharmaceuticals · Regeneron Pharma (REGN) · Science
X